Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Rhythm Biosciences Ltd

RHY.AX ✗ NOT COMPLIANTFree checks used up today ☆ Track — members

ASX · Healthcare · Biotechnology & Medical Research ·

Australia Micro Cap Analyst: N/A

Last Close

$0.05

▲ +0.00%

Market Cap $16.66M · Vol 6.09K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$16.66M

Micro Cap

Div Yield

N/A

EPS Growth

N/A

YoY

RSI (14)

25.93

Momentum

Beta

1.41

vs Market

52W High

$0.20

76.03% below

52W Low

$0.04

13.95% above

Volume

6.09K

Avg 238.90K

P/B

9.11

Price-to-book

ROE

N/A

Return on equity

Free Float

76.00%

Public shares

Shariah Compliance8 STANDARDS

✗ Rhythm Biosciences Ltd (RHY.AX) stock is currently not Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does RHY.AX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+0.00%

-17.28%

-16.25%

-60.59%

YTD

-50.37%

-29.47%

-56.67%

-94.97%

Financials & Valuation

TTM · Annual

Total Revenue	$1.20M
Net Income	$-4,103,010.00
Revenue Growth (YoY)	+24.02%
Gross Margin	-143.40%
Operating Margin	-334.10%
Net Profit Margin	-341.26%
ROE	N/A
ROA · ROIC	-155.88% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	17.50
P/B	9.11
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	353.87M

Technical Indicators

50-Day SMA	$0.06
200-Day SMA	$0.09
RSI (14)	25.93
Beta	1.41
52-Week High	$0.20
52-Week Low	$0.04

Volume Today	6.09K
Avg Daily Volume (30D)	238.90K
Relative Volume	0.03x
Volatility (10D)	55.09
Volatility (30D)	39.96
Free Float	76.00%

Analyst Consensus

N/A

Current Price $0.05

Mean Target N/A

52W Low$0.04 52W High$0.20

Current

Target

$0.04 $0.20

Current Analyst target

· 0 analysts

Identifiers

ExchangeASX

FIGIBBG00HZRNTS5

ISINAU000000RHY2

CountryAustralia

Sub-IndustryBio Diagnostics & Testing

Earnings DateN/A

TypeStocks

Instrument TypeFULLPAID Fully Paid Ordinary

Similar Halal Stocks

IOVA Iovance Biotherapeutics Inc -3.28% ADPT Adaptive Biotechnologies Corporation -3.63% VCYT Veracyte, Inc. -0.39% CDNA CareDx, Inc. -2.23% 300676.SZ BGI Genomics Co Ltd -1.98%

Company Profile

Rhythm Biosciences Ltd is an Australia-based medical diagnostics company. The Company is engaged in delivering simple, affordable blood tests for accurate and early detection of cancers. It is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer and saving lives. The Company’s blood-based technology, a blood test for the detection of Colorectal Cancer (CRC). The ColoSTAT Test-Kit measures five specific protein biomarkers that indicate the likelihood of CRC. The test is an alternative for individuals who are unable or unwilling to participate in current screening programs. It is being updated to meet the IVDR (In vitro diagnostic medical devices regulation) regulatory standards. Its geneType platform personalized predictive test portfolio that uses a combination of genomic and clinical information to predict risk of chronic disease development.